Lawrence, W Jr, Donegan, WL, Natarajan, N, et al. Adult soft tissue sarcomas: a pattern of care survey of the American College of Surgeons. Ann Surg 1987;205(4):349–359.Google Scholar

Heslin, MJ, Lewis, JJ, Woodruff, JM, Brennan, MF. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 1997;4(5):425–431.Google Scholar

Lewis, JJ, Leung, D, Espat, J, Woodruff, JM, Brennan, MF. Effect of reresection in extremity soft tissue sarcoma. Ann Surg 2000;231(5):655–663.CrossRefGoogle ScholarPubMed

Melendez, M, Brandt, K, Evans, GR. Sciatic nerve reconstruction: limb preservation after sarcoma resection. Ann Plast Surg 2001;46(4):375–381.Google Scholar

Brooks, AD, Gold, JS, Graham, D, et al. Resection of the sciatic, peroneal, or tibial nerves: assessment of functional status. Ann Surg Oncol 2002;9(1):41–47.CrossRefGoogle ScholarPubMed

Saint-Cyr, M, Langstein, HN. Reconstruction of the hand and upper extremity after tumor resection. J Surg Oncol 2006;94(6):490–503.Google Scholar

Baxter, BT, Mahoney, C, Johnson, PJ, et al. Concomitant arterial and venous reconstruction with resection of lower extremity sarcomas. Ann Vasc Surg 2007;21(3):272–279.Google Scholar

Adelani, MA, Holt, GE, Dittus, RS, Passman, MA, Schwartz, HS. Revascularization after segmental resection of lower extremity soft tissue sarcomas. J Surg Oncol 2007; 95(6):455–460.Google Scholar

Ghert, MA, Davis, AM, Griffin, AM, et al. The surgical and functional outcome of limb-salvage surgery with vascular reconstruction for soft tissue sarcoma of the extremity. Ann Surg Oncol 2005;12(12):1102–1110.CrossRefGoogle ScholarPubMed

Ariyan, S. The functional pectoralis major musculocutaneous island flap for head and neck reconstruction. Plast Reconstr Surg 1990;86(4):807–808.Google Scholar

Ross, DA, Hundal, JS, Son, YH, et al. Microsurgical free flap reconstruction outcomes in head and neck cancer patients after surgical extirpation and intraoperative brachytherapy. Laryngoscope 2004;114(7):1170–1176.Google Scholar

Duman, H, Evans, GR, Reece, G, et al. Brachytherapy: reconstructive options and the role of plastic surgery. Ann Plast Surg 2000;45(5):477–480.CrossRefGoogle ScholarPubMed

Bui, DT, Cordeiro, PG, Hu, QY, et al. Free flap reexploration: indications, treatment, and outcomes in 1193 free flaps. Plast Reconstr Surg 2007;119(7):2092–2100.Google Scholar

Kooby, DA, Antonescu, CR, Brennan, MF, Singer, S. Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations. Ann Surg Oncol 2004;11(1):78–84.Google Scholar

Bowne, WB, Antonescu, CR, Leung, DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000;88(12):2711–2720.Google Scholar

Merchant, NB, Lewis, JJ, Woodruff, JM, Leung, DH, Brennan, MF. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 1999;86(10):2045–2052.Google Scholar

Rosenberg, SA, Tepper, J, Glatstein, E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196(3):305–315.Google Scholar

Williard, WC, Hajdu, SI, Casper, ES, Brennan, MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;215(3):269–275.Google Scholar

Pisters, PW, Harrison, LB, Leung, DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14(3):859–868.Google Scholar

O’Sullivan, B, Davis, AM, Turcotte, R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359(9325):2235–2241.Google Scholar

Yang, JC, Chang, AE, Baker, AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16(1):197–203.Google Scholar

Baldini, EH, Goldberg, J, Jenner, C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999;17(10):3252–3259.CrossRefGoogle ScholarPubMed

Lin, PP, Schupak, KD, Boland, PJ, Brennan, MF, Healey, JH. Pathologic femoral fracture after periosteal excision and radiation for the treatment of soft tissue sarcoma. Cancer 1998;82(12):2356–2365.Google Scholar

Alektiar, KM, Hong, L, Brennan, MF, Della-Biancia, C, Singer, S. Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results. Int J Radiat Oncol Biol Phys 2007;68(2):458–464.Google Scholar

Rosenberg, SA, Tepper, J, Glatstein, E, et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 1983;52(3):424–434.Google Scholar

Chang, AE, Kinsella, T, Glatstein, E, et al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol 1988;6(9):1491–1500.Google Scholar

Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350(9092):1647–1654.Google Scholar

Elias, A, Ryan, L, Sulkes, A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7(9):1208–1216.Google Scholar

Elias, AD, Eder, JP, Shea, T, et al. High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol 1990;8(1):170–178.CrossRefGoogle ScholarPubMed

Antman, KH, Elias, A, Ryan, L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol 1990;17(2 Suppl 4):68–73.Google Scholar

Frustaci, S, Gherlinzoni, F, De Paoli, A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19(5):1238–1247.Google Scholar

Frustaci, S, De Paoli, A, Bidoli, E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65(Suppl 2):80–84.Google Scholar

Grobmyer, SR, Maki, RG, Demetri, GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2004;15(11):1667–1672.Google Scholar

Chang, HR, Hajdu, SI, Collin, C, Brennan, MF. The prognostic value of histologic subtypes in primary extremity liposarcoma. Cancer 1989;64(7):1514–1520.Google Scholar

Gebhard, S, Coindre, JM, Michels, JJ, et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2002;26(5):601–616.CrossRefGoogle Scholar

Antonescu, CR, Tschernyavsky, SJ, Decuseara, R, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 2001;7(12):3977–3987.Google Scholar

McCormick, D, Mentzel, T, Beham, A, Fletcher, CD. Dedifferentiated liposarcoma: clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol 1994;18(12):1213–1223.Google Scholar

Henricks, WH, Chu, YC, Goldblum, JR, Weiss, SW. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 1997;21(3):271–281.Google Scholar

Eilber, FC, Eilber, FR, Eckardt, J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004;240(4):686–695; discussion 695–697.Google Scholar

Lewis, JJ, Antonescu, CR, Leung, DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000;18(10):2087–2094.Google Scholar

Eilber, FC, Brennan, MF, Eilber, FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007;246(1):105–113.Google Scholar

Mentzel, T, Calonje, E, Wadden, C, et al. Myxofibrosarcoma: clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 1996;20(4):391–405.Google Scholar

Angervall, L, Kindblom, LG, Merck, C. Myxofibrosarcoma: a study of 30 cases. Acta Pathol Microbiol Scand A 1977;85A(2):127–140.Google Scholar

Huang, HY, Lal, P, Qin, J, Brennan, MF, Antonescu, CR. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol 2004;35(5):612–621.Google Scholar

Waters, B, Panicek, DM, Lefkowitz, RA, et al. Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease. AJR Am J Roentgenol 2007;188(2):W193–W198.Google Scholar

Mundt, KA, Dell, LD, Austin, RP, et al. Historical cohort study of 10 109 men in the North American vinyl chloride industry, 1942–72: update of cancer mortality to 31 December 1995. Occup Environ Med 2000;57(11):774–781.Google Scholar

Lee, FI, Smith, PM, Bennett, B, Williams, DM. Occupationally related angiosarcoma of the liver in the United Kingdom 1972–1994. Gut 1996;39(2):312–318.Google Scholar

Strobbe, LJ, Peterse, HL, van Tinteren, H, Wijnmaalen, A, Rutgers, EJ. Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome: an unforseen sequela. Breast Cancer Res Treat 1998;47(2):101–109.Google Scholar

Cha, C, Antonescu, CR, Quan, ML, Maru, S, Brennan, MF. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004;239(6):903–909; discussion 909–910.Google Scholar

Stewart, FW, Treves, N. Classics in oncology: lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. CA Cancer J Clin 1981;31(5):284–299.Google Scholar

Naka, N, Ohsawa, M, Tomita, Y, et al. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol 1996;61(3):170–176.3.0.CO;2-8>CrossRefGoogle ScholarPubMed

Skubitz, KM, Haddad, PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005;104(2):361–366.CrossRefGoogle ScholarPubMed

Fata, F, O’Reilly, E, Ilson, D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86(10):2034–2037.Google Scholar

Vauthey, JN, Woodruff, JM, Brennan, MF. Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): a 10-year experience. Ann Surg Oncol 1995;2(2):126–131.CrossRefGoogle Scholar

Grier, HE, Krailo, MD, Tarbell, NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348(8):694–701.Google Scholar

Linet, MS, Ries, LA, Smith, MA, Tarone, RE, Devesa, SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 1999;91(12):1051–1058.CrossRefGoogle ScholarPubMed

Paulino, AC, Okcu, MF. Rhabdomyosarcoma. Curr Probl Cancer 2008;32(1):7–34.Google Scholar

Lewis, JJ, Leung, D, Woodruff, JM, Brennan, MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228(3):355–365.CrossRefGoogle ScholarPubMed

Singer, S, Antonescu, CR, Riedel, E, Brennan, MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003;238(3):358–370; discussion 370–371.Google Scholar

Fabre-Guillevin, E, Coindre, JM, Somerhausen Nde, S, et al. Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas. Cancer 2006;106(12):2725–2733.Google Scholar

Karakousis, CP, Velez, AF, Gerstenbluth, R, Driscoll, DL. Resectability and survival in retroperitoneal sarcomas. Ann Surg Oncol 1996;3(2):150–158.Google Scholar

Tepper, JE, Suit, HD, Wood, WC, et al. Radiation therapy of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1984;10(6):825–830.Google Scholar

Sindelar, WF, Kinsella, TJ, Chen, PW, et al. Intraoperative radiotherapy in retroperitoneal sarcomas: final results of a prospective, randomized, clinical trial. Arch Surg 1993;128(4):402–410.Google Scholar

Pawlik, TM, Pisters, PW, Mikula, L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol 2006;13(4):508–517.CrossRefGoogle ScholarPubMed

Dematteo, RP, Gold, JS, Saran, L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008;112(3):608–615.Google Scholar

Raut, CP, DeMatteo, RP. Prognostic factors for primary GIST: prime time for personalized therapy? Ann Surg Oncol 2008;15(1):4–6.Google Scholar

Hirota, S, Isozaki, K, Moriyama, Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279(5350):577–580.Google Scholar

Heinrich, MC, Corless, CL, Demetri, GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21(23):4342–4349.Google Scholar

Antonescu, CR, Sommer, G, Sarran, L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9(9):3329–3337.Google Scholar

Heinrich, MC, Corless, CL, Duensing, A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299(5607):708–710.Google Scholar

Dematteo, RP, Owzar, K, Maki, RG, et al. Adjuvant imatinib mesylate increases recurrence-free survival (RFS) in patients with completely localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III Trial ACOSOG Z9001. Proc Am Soc Clin Oncol 2007;Abstract No(10079).Google Scholar

Verweij, J, Casali, PG, Zalcberg, J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364(9440):1127–1134.CrossRefGoogle ScholarPubMed

DeMatteo, RP, Maki, RG, Singer, S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245(3):347–352.Google Scholar